Natriuretic Peptide Blood Tests Are Essential for Diagnosing Heart Failure — Especially in Diabetic Patients | Research

The takeaway

BNP and NT-proBNP measurements are guideline-recommended tools for heart failure diagnosis, prognosis, and risk stratification, with particular value in diabetic patients at high risk of developing heart failure.

BNP <100 pg/mL rules out HF
Emergency setting threshold with high negative predictive value per 2023 ESC consensus

What the researchers found

BNP and NT-proBNP are validated biomarkers for heart failure diagnosis and prognosis, with specific clinical thresholds for ruling out HF, and provide additional value in diabetic patients for cardiovascular risk stratification and treatment selection.

Why it matters

Heart failure in diabetic patients is common but often diagnosed late. Natriuretic peptide testing can identify at-risk patients before symptoms develop, enabling earlier use of protective medications and potentially preventing overt heart failure.

The numbers in context

BNP and NT-proBNP have high negative predictive value for heart failure; international guidelines recommend their measurement.

How the study worked

Clinical review synthesizing evidence on natriuretic peptide utility in heart failure management, incorporating the 2023 ESC consensus recommendations with focus on diabetes comorbidity.

Who was studied

Heart failure patients, particularly those with diabetes

What this study cannot tell us

Review article — no new data. Natriuretic peptide interpretation is complicated by obesity (lower values), kidney disease (higher values), age, and sex. Not all clinical settings have access to rapid NP testing. Cut-off values may need population-specific adjustment.

How to read the evidence

Strong evidence — natriuretic peptides are guideline-recommended biomarkers supported by extensive clinical trial data and the 2023 ESC consensus statement.

When this study was published

Published in 2024. Incorporates the latest 2023 ESC consensus recommendations on natriuretic peptide thresholds.

The bigger picture

Natriuretic peptides represent one of the clearest examples of peptide biomarkers transforming clinical practice. Their role is expanding from diagnosis to guiding preventive therapy — particularly in selecting cardiorenal-protective drugs for high-risk diabetic patients.

Questions still open

Should routine natriuretic peptide screening be recommended for all diabetic patients?
How should NP values be interpreted in obese diabetic patients on GLP-1RAs (who may be losing weight)?
Can serial NP monitoring guide therapy escalation in pre-clinical heart failure?

Common questions

What are BNP and NT-proBNP tests?

These are blood tests that measure natriuretic peptides — hormones your heart releases when it's under stress or not pumping well. Low levels can reliably rule out heart failure. High levels suggest heart problems and increased risk of cardiovascular events. They're quick, widely available, and recommended by major heart guidelines.

Why are these tests especially important for people with diabetes?

Diabetic patients have a much higher risk of developing heart failure, often without obvious early symptoms. Natriuretic peptide testing can identify at-risk individuals before heart failure develops, allowing doctors to start protective medications (like GLP-1 drugs or SGLT2 inhibitors) earlier — potentially preventing heart failure altogether.

Read the original research

The Role of Natriuretic Peptides in the Management of Heart Failure with a Focus on the Patient with Diabetes.

Journal of clinical medicine, 13(20)

View on PubMed ↗Publisher’s paper ↗

Citation

Vergani, Michela; Cannistraci, Rosa; Perseghin, Gianluca; Ciardullo, Stefano. (2024). The Role of Natriuretic Peptides in the Management of Heart Failure with a Focus on the Patient with Diabetes.. Journal of clinical medicine, 13(20). https://doi.org/10.3390/jcm13206225